Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
Condition(s):Multiple MyelomaLast Updated:May 27, 2022Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Multiple MyelomaLast Updated:May 27, 2022Active, not recruiting
Condition(s):Multiple MyelomaLast Updated:April 23, 2013Completed
Condition(s):Multiple Myeloma in RelapseLast Updated:April 6, 2016Completed
Condition(s):Relapsed and Refractory; Diffuse Large B Cell LymphomaLast Updated:July 25, 2019Completed
Condition(s):AL Amyloidosis; AmyloidosisLast Updated:February 29, 2024Recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:December 8, 2022Completed
Condition(s):Refractory B-Cell LymphomaLast Updated:January 31, 2019Unknown status
Condition(s):Refractory B-Cell LymphomaLast Updated:January 30, 2019Unknown status
Condition(s):Refractory B-Cell LymphomaLast Updated:January 31, 2019Unknown status
Condition(s):Refractory B-Cell LymphomaLast Updated:January 31, 2019Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.